GI-108

GI-108 · GI Innovation, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GI-108, covering 2025-09-15 to 2025-09-15. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

See pricing